商標ウォッチ

TOP｜特許｜意匠｜商標

商標ウォッチ Twitter

公開日2025-02-27
公報種別公開国際商標公報
国際登録番号1627171
国際登録日
区分第5類(薬剤),第42類(科学・技術)
商品役務Radioisotopes for medical purposes; diagnostic and therapeutic radioisotopes and radiochemicals for medical purposes; all of the foregoing for use in targeted therapy for cancer patients and radio chemistry research.,Scientific research and development of radioisotopes suitable for diagnostic and therapeutic medical use; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for medical use; scientific laboratory services; scientific research and development of radioisotopes suitable for diagnostic and therapeutic and medical use; Scientific research and development of radioisotopes suitable for radiopharmaceuticals; scientific research and development of new procedures and experiments for the discovery, identification or improvement of radioisotopes for radiopharmaceuticals; scientific research and development and engineering services in the field of radioisotopes, radioisotope generators, and linkers suitable for radiopharmaceuticals; scientific research and development in the isolation and capture of radioisotopes suitable for radiopharmaceuticals.
基礎出願番号90861365
基礎出願日2021-08-02
基礎出願国US
出願人TerraPower, LLC
OCRテキストTPI
OCRテキスト2
OCRについて

この商標をJ-PlatPatで参照する

関連商標

TerraPower, LLC

Bayer Consumer Care AG

Triticum Exploitatie B.V.

JADRAN - GALENSKI LABORATORIJ d.d.

ROXALL Medizin GmbH

ROXALL Medizin GmbH

ROXALL Medizin GmbH

Orion Corporation

BOLERO & Co Ltd.

Luxatemp MaxProtect

Natural Innovations Group Pty Ltd

Perfect Care Distribution

Boehringer Ingelheim Vetmedica GmbH

BIG SHOT DEVELOPMENTS LTD.

Bausch Health Ireland Limited

Merz Pharma GmbH & Co. KGaA

DAEWOONG CO., LTD.

PECTEN GROUP S.R.L.

INTIACT REGENERATIVE

Hermes Arzneimittel GmbH

TerraPower, LLC

| TERRAPOWER ISOTOPES

Ursapharm Arzneimittel GmbH

PAUL HARTMANN AG

Novo Nordisk A/S

AFT PHARMACEUTICALS LIMITED

INTERSALES COMPANY, naamloze vennootschap

続きを見る